Sana Biotechnology
SANA
123 hedge funds and large institutions have $804M invested in Sana Biotechnology in 2023 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 38 increasing their positions, 41 reducing their positions, and 10 closing their positions.
6,590% more call options, than puts
Call options by funds: $8.23M | Put options by funds: $123K
88% more capital invested
Capital invested by funds: $427M → $804M (+$377M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
3% more funds holding
Funds holding: 120 → 123 (+3)
2.16% more ownership
Funds ownership: 68.31% → 70.47% (+2.2%)
7% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$43.2M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$8.83M |
| 3 |
CC
Casdin Capital
New York
|
+$4.32M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.53M |
| 5 |
Millennium Management
New York
|
+$1.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$8.47M |
| 2 |
JP Morgan Chase
New York
|
-$6.94M |
| 3 |
Public Sector Pension Investment Board (PSP Investments)
Montreal,
Quebec, Canada
|
-$5.93M |
| 4 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$5.47M |
| 5 |
State Street
Boston,
Massachusetts
|
-$4.93M |
SANA Hedge Fund Activity: Q2 2023 in Review
123 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q2 2023, worth a combined $804M — up 88% from $427M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new SANA positions and 10 closed out — a net gain of 3 holders — while 38 added to existing stakes and 41 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $43.2M. The largest seller was Citadel Advisors, cutting an estimated $8.47M.
- 123 institutional investors held Sana Biotechnology (SANA) as of Q2 2023, up from 120 in Q1 2023.
- Funds reported $804M of Sana Biotechnology stock for Q2 2023, up 88% quarter-over-quarter.
- 13 funds opened new Sana Biotechnology positions in Q2 2023 and 10 closed out, a net change of +3 holders.
- The largest Sana Biotechnology buyer in Q2 2023 was Fidelity Investments, an estimated $43.2M added.
- The largest Sana Biotechnology seller in Q2 2023 was Citadel Advisors, an estimated $8.47M sold.
Based on aggregated 13F filings for Q2 2023.